INSM Projected Dividend Yield

Insmed Inc ( NASDAQ : INSM )

Insmed is a biopharmaceutical company. Co.'s commercial product, ARIKAYCE, is approved in the U.S. for the treatment of Mycobacterium avium complex lung disease and in Europe for the treatment of nontuberculous mycobacterial lung infections. Co.'s pipelines include: brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis and other neutrophil-mediated diseases; and treprostinil palmitil inhalation powder, an inhaled formulation of the treprostinil prodrug treprostinil palmitil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

20 YEAR PERFORMANCE RESULTS